SECTION 1: OUR VISION

Letter from the ILCA President
Page 3

Mission
Page 5

Vision
Page 6

SECTION 2: ACHIEVEMENTS

Testimonials
Page 7

SECTION 3: PERFORMANCES

ILCA in Numbers
Page 9

SECTION 4: LEADERSHIP & VOLUNTEERS

ILCA Board
Page 13

SECTION 5: CONTACTS

Get In Touch
Page 16
ILCA has defined a clear strategy to lead a global community of physicians, scientists, allied professionals and patients through education, research and advocacy with the goal to better prevent and treat liver cancer.

In 2022, we took a series of solid and successful steps to execute against that strategy, strengthening our educational portfolio, expanding our partner ecosystem, and returning our annual conference to an in-person activity. Our performance was driven by our unique ability to combine outstanding science and a multi-disciplinary network, thereby creating value for our members and partners. We entered 2022 with a series of clear but ambitious goals: to strengthen our educational portfolio, broaden our influence, and modernise our governance model. Our strong performance is a direct reflection of our ability to execute against these goals.

Strengthening our educational portfolio

Throughout the year, we continued to align our educational offerings with the wishes and needs of our community. Our content-centric approach starts with our new monthly podcast series, which allows our members to listen to the latest science or an explanation of a particular technique in a timely and highly accessible manner. They have become very popular and I am delighted that our 2023 podcast series will build further on this success.

Our webinar series has enjoyed similar such success with attendees joining from all over the world. Featuring some of the very best Key Opinion Leaders in Liver cancer, the webinars have a strong reputation for best-in-class expertise sharing and discussion.

To complement our digital education, we were able to offer in-person education again - the first time since the Covid pandemic. Our inaugural Single Topic Workshop on HCC risk stratification and surveillance was finally able to be held in Paris, attracting an impressive number of attendees for such a niche topic meeting. With participants joining from North America, Europe and Asia, I am pleased that ILCA’s convening power remains strong. Our 16th annual conference, held in Madrid in September, took this a step further with a record number of first-time attendees. Featuring the usual array of cutting-edge science and masterclass presentations, the conference was our first one in hybrid format where we were able to open the conference up to those unable to join us in person. As we move forward into 2023, we remain committed to making the ‘world’s best liver cancer meeting’ as inclusive as possible.

Broadening our influence

Our efforts here have been designed toward outreach and creating partnerships of value, part of a larger advocacy shift at ILCA to make patients the heart of our decisions, not only the centre of our work. One example of this was seen in ILCA’s participation in
Letter from the ILCA President

a high-level EU Parliament workshop during October’s Liver Cancer Awareness Month. We believe that ILCA has a unique ability to bring together all the necessary stakeholders in liver cancer and we are developing our ecosystem of sister societies, patient organisations and corporate partners to this end. We are seeing high demand for our capabilities in this area and, through an impressive array of world-renowned experts, 2023 will see ILCA continue developing its landmark series of position papers focused on patient access to treatment.

Modernising our governance model

At ILCA, we have always understood that our responsibilities extend far beyond leading our community and providing it with the best in professional learning and networking. Among the most prevalent themes in our society today is Diversity and Inclusion. That is why we undertook a review of our governance model and embrace our leadership role in promoting the values important to our ILCA community. I am delighted that, in our new bylaws, ILCA has committed to be even more representative, by ensuring that there is broad specialism, geographic, gender and generational representation in our leadership. This is imperative for the health of our association and for our future relevance.

In 2023 we want to make the world healthier...from a liver cancer perspective

ILCA has a unique opportunity: we can be the catalyst that better prevents and treats liver cancer. My board and I are dedicated to this, pursuing initiatives that can make a difference and committed to bringing value to our members. We are open to partnership and open to ideas. Most of all, we are open to you and invite you to join us in making liver cancer patients healthier. With your support, ILCA is positioned to lead efforts to better prevent and treat liver cancer for decades to come. I look forward to hearing from you!

Jessica Zucman-Rossi
ILCA President 2021 - 2023
Professor of Medicine, Oncology, Universite Paris Descartes
Head of INSERM Unit, Functional Genomic of Solid Tumours
Centre de Recherche des Cordeliers, Paris, France
Our mission is to lead a global community of physicians, scientists and allied professionals through education and research to better prevent and treat liver cancer. We will promote novel pathogenic, diagnostic, and therapeutic interventions for liver cancer by taking a transversal approach to research and bringing together scientists, physicians and allied professionals from all interrelated fields.
We come together for better liver cancer patient treatment and care.

Liver cancer incidence rates are rapidly increasing across the world. And, because it is rarely detectable early when it is most treatable, any liver cancer is difficult to cure. It is all about strengthening our global reach through education and research to better serve our members, our partners, and ultimately, our patients.
2. ACHIEVEMENTS

2022 was a very active year for us because all the experts that belong to the association were working together to disseminate new activities and new results that were obtained through the basic research and the scientific work, but also to translate the results to the clinical care of patients.

And thanks to this success, we look forward to meeting you also in 2023 and to continue and to include you in our activity.

At ILCA, we created the ILCA Patient Advocacy team to give voice to liver cancer patients and increase awareness of the disease among the general population.

Young trainees are central for the mission of ILCA. Our recently launched Y-ILCA group is the forum for trainees to share experiences, education and opportunities for their future career in liver cancer.
2. ACHIEVEMENTS

At ILCA, what we have decided as a group is to have patients at the core of our decisions. What we have done so far is we have started partnership with some European and global liver patients societies and we have produced a document setting the frame for future actions in this field.

Our education committee has actually done a number of events for our patients and also for ILCA. The first one is that we have announced the TACE consensus and secondly we have organized a number of webinars.

The single topic workshop that we held in June in Paris this year was looking particularly at risk stratification and surveillance. It was very well attended with fantastic speakers from across the world.

Our education committee has actually done a number of events for our patients and also for ILCA. The first one is that we have announced the TACE consensus and secondly we have organized a number of webinars.

The single topic workshop that we held in June in Paris this year was looking particularly at risk stratification and surveillance. It was very well attended with fantastic speakers from across the world.

The ILCA communications committee in 2022 focused mainly on two activities, podcast and the liver cancer awareness month campaign. All these activities have the aim of increasing the awareness and the knowledge of liver cancer, both hepatocellular carcinoma and cholangiocarcinoma.
3. PERFORMANCES

Educational content in numbers

- 14 Podcasts
- 2 Events
- 9 Webinars
ILCA in numbers

2400* HOURS
that members dedicated to ILCA

Education
Network
Research

28 PROJECTS
delivered

1060* PEOPLE
Involved in ILCA's Education initiatives

6 AWARDEES

3. PERFORMANCES

ILCA Annual Report 2022
3. PERFORMANCES

Members per discipline

- Hepatology: 41%
- Oncology: 19%
- Internal Medicine: 7%
- Molecular biology: 5%
- Gastroenterology: 4%
- Radiology: 5%
- Basic Research: 8%
- Epidemiology: 8%
- Surgery: 1%
- Pathology: 1%
Reach in numbers

› Members per Continent

- Europe: 40%
- Asia: 30%
- South America: 20%
- North America: 20%
- Australia: 4%
- Africa: 4%
Leadership and volunteers who belong to ILCA undoubtedly contribute to improved patient care. The ILCA Leadership consists of several volunteer committees formed by prominent ILCA members joining forces to advance the mission of advancing liver cancer science and care worldwide.

**ILCA Executive Committee 2022**

Jessica Zucman-Rossi  
President

Tim Meyer  
President Elect

Augusta Villanueva  
Executive Secretary

Lorenza Rimassa  
Treasurer

**Governing Board**

The Governing Board consists of the Executive Committee and the Council members, who, as stipulated in the ILCA Bylaws, represent different liver cancer disciplines and countries.
4. LEADERSHIP & VOLUNTEERS

Council members

Stephen Chan
Hong Kong

Valerie Chew
Singapore

R. Kate Kelley
USA

Laura Kulik
USA

Jeong Min Lee
Republic of Korea

Amaia Lujambio
USA

Valérie Paradis
France

Gonzalo Sapisachin
Canada

Amit Singal
USA
The world’s leading liver cancer meeting

ILCA 2023

17th Annual Conference
7-9 September, 2023 | Amsterdam, The Netherlands

ilcalive.org #ILCA23